Zinplava Tackles Toxins Of Hard-to-Treat C. Difficile.

February 7, 2017 at 3:41 pm

Manag Care. 2017 Jan;26(1):30-31.

Morrow T.

Abstract

Merck has recently received FDA approval for bezlotoxumab (Zinplava), as a treatment to reduce recurrence of C. diffcile in patients 18 years of age or older who are receiving antibiotic treatment for the infection and for whom there is a high risk of recurrence.

FULL TEXT

https://www.managedcaremag.com/linkout/2017/1/30

Advertisements

Entry filed under: Bacterias, Biológicos, Health Care-Associated Infections, Infecciones gastrointestinales, Infecciones nosocomiales, Metodos diagnosticos, Update.

Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2017


Calendar

February 2017
M T W T F S S
« Jan   Mar »
 12345
6789101112
13141516171819
20212223242526
2728  

Most Recent Posts


%d bloggers like this: